Insights

Gathering insights about FibroBiologics…

Similar companies to FibroBiologics

FibroBiologics Tech Stack

FibroBiologics uses 8 technology products and services including NitroPack, MySQL, Shopify, and more. Explore FibroBiologics's tech stack below.

NitroPack
Caching
MySQL
Database
Shopify
E-commerce
JSON-LD
Javascript Frameworks
JSZip
Javascript Libraries
jQuery
Javascript Libraries
Priority Hints
Performance
Bokeh
Visualisation Software

Media & News

FibroBiologics to Present at the DealFlow Discovery Conference
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic City, New Jersey.
Jan 20, 2026 | www.globenewswire.com
FibroBiologics CEO Issues Letter to Shareholders
HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders. Fellow Shareholders, Looking back on 2025, I'm reminded of something I've always believed: the best way to predict the future is to invent it.
Jan 07, 2026 | www.globenewswire.com
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference taking place January 11, 2026, at The St. Regis in San Francisco, California.
Jan 06, 2026 | www.globenewswire.com
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced positive preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement in recovering intervertebral disc integrity and preventing degeneration in animal models of degenerative disc disease. These preclinical findings represent a major advancement for FibroBiologics' regenerative medicine pipeline and highlight the potential of FSdC spheroids to address unmet needs in spinal health.
Jan 05, 2026 | www.globenewswire.com
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CYPS317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. This IND filing represents a major advancement for FibroBiologics' chronic inflammatory disease pipeline and follows a series of positive IND-enabling preclinical results demonstrating the potential of fibroblast spheroids to significantly reduce psoriasis disease severity and relapse in preclinical models.
Dec 31, 2025 | www.globenewswire.com
FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Down 42.8% in December
FibroBiologics Inc. (NASDAQ: FBLG - Get Free Report) saw a significant drop in short interest in December. As of December 15th, there was short interest totaling 795,335 shares, a drop of 42.8% from the November 30th total of 1,389,641 shares. Based on an average daily volume of 1,960,972 shares, the days-to-cover ratio is currently 0.4 days.
Dec 27, 2025 | www.defenseworld.net
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 5,227,275 shares of its common stock at an offering price of $0.33 per share of common stock. Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate of 5,227,275 shares of common stock at an exercise price of $0.33 per share.
Dec 16, 2025 | www.globenewswire.com

FibroBiologics's Email Address Formats

FibroBiologics uses at least 1 format(s):

FibroBiologics Email Formats	Example	Percentage
First.Last@fibrobiologics.com	John.Doe@fibrobiologics.com	50%
First.Last@fibrobiologics.com	John.Doe@fibrobiologics.com	50%

Frequently Asked Questions

Where is FibroBiologics's headquarters located?

FibroBiologics's main headquarters is located at 16815 Royal Crest Drive, Suite 100. The company has employees across 1 continents, including North America.

What is FibroBiologics's stock symbol?

FibroBiologics is a publicly traded company; the company's stock symbol is FBLG.

What is FibroBiologics's official website and social media links?

FibroBiologics's official website is fibrobiologics.com and has social profiles on LinkedIn Crunchbase.

What is FibroBiologics's SIC code NAICS code?

FibroBiologics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does FibroBiologics have currently?

As of January 2026, FibroBiologics has approximately 15 employees across 1 continents, including North America. Key team members include Chief Financial Officer: J. D.Chief Scientific Officer: H. K.Chairman/Ceo/Founder: P. O.. Explore FibroBiologics's employee directory with LeadIQ.

What industry does FibroBiologics belong to?

FibroBiologics operates in the Biotechnology Research industry.

What technology does FibroBiologics use?

FibroBiologics's tech stack includes NitroPackMySQLShopifyJSON-LDJSZipjQueryPriority HintsBokeh.

What is FibroBiologics's email format?

FibroBiologics's email format typically follows the pattern of First.Last@fibrobiologics.com. Find more FibroBiologics email formats with LeadIQ.

How much funding has FibroBiologics raised to date?

As of January 2026, FibroBiologics has raised $30M in funding. The last funding round occurred on Dec 23, 2024 for $30M.

FibroBiologics

Q: What is FibroBiologics's official website and social media links?

FibroBiologics's official website is fibrobiologics.com. FibroBiologics has social profiles on LinkedIn.

Q: How many employees does FibroBiologics have currently?

FibroBiologics has approximately 15 employees.

Q: What technology does FibroBiologics use?

FibroBiologics's tech stack includes NitroPack, Web Vitals, Swiper, three.js, JSON-LD.

Biotechnology ResearchTexas, United States11-50 Employees

FibroBiologics (Nasdaq: FBLG) is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer.  FibroBiologics represents the next generation of medical advancement in cell therapy.

Company Overview

Headquarters: 16815 Royal Crest Drive, Suite 100
Website: fibrobiologics.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: FBLG
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 11-50

Media & News

Funding & Financials

$30M
FibroBiologics has raised a total of $30M of funding over 3 rounds. Their latest funding round was raised on Dec 23, 2024 in the amount of $30M.
$1M$10M
FibroBiologics's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$30M
FibroBiologics has raised a total of $30M of funding over 3 rounds. Their latest funding round was raised on Dec 23, 2024 in the amount of $30M.
$1M$10M
FibroBiologics's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to FibroBiologics

Roche

Bristol-Myers Squibb

Sanofi

Johnson & Johnson

Moderna

Wyeth Pharmaceuticals

AstraZeneca

AbbVie

Biogen

Gilead Sciences

Novartis

Amgen

Eli Lilly and Company

FibroBiologics Tech Stack

Media & News

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Down 42.8% in December

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics's Email Address Formats

Frequently Asked Questions

Where is FibroBiologics's headquarters located?

What is FibroBiologics's stock symbol?

What is FibroBiologics's official website and social media links?

What is FibroBiologics's SIC code NAICS code?

How many employees does FibroBiologics have currently?

What industry does FibroBiologics belong to?

What technology does FibroBiologics use?

What is FibroBiologics's email format?

How much funding has FibroBiologics raised to date?

FibroBiologics

Company Overview

Media & News

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?